Eptinezumab

Eptinezumab, sold under the brand name Vyepti, is a medication used for the preventive treatment of migraine in adults.[3] It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta.[3][4][5] It is administered by intravenous infusion.[3] Eptinezumab was approved for medical use in the United States in February 2020.[6][7] Contents 1 History 2 ... [wikipedia]